UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. ___)*
ALBIREO PHARMA, INC
(Name of Issuer)

COMMON STOCK, PAR VALUE $.001 PER SHARE
(Title of Class of Securities)

01345P106
(CUSIP Number)

March 1, 2022
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

[_] Rule 13d-1(b)

[x] Rule 13d-1(c)

[_] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person?s
initial filing on this form with
respect to the subject class of securities, and for any subsequent amendment co
ntaining information which would
alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deeme
d to be ?filed? for the purpose of
Section 18 of the Securities Exchange Act of 1934 (?Act?) or otherwise subject
to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).

SCHEDULE 13G

CUSIP No.
01345P106

1
Names of Reporting Persons

Chicago Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)

(a)  [ ]
(b)  [ ]
3
Sec Use Only


4
Citizenship or Place of Organization

Illinois
Number of
Shares
Beneficially
Owned by Each
Reporting Person
With:

5
  Sole Voting Power


 971,885

6
  Shared Voting Power


  -0-

7
  Sole Dispositive Power


 971,885

8
  Shared Dispositive Power


  -0-
9
Aggregate Amount Beneficially Owned by Each Reporting Person


 971,885
10
Check box if the aggregate amount in row (9) excludes certain shares
(See Instructions)

[ ]
11
Percent of class represented by amount in row (9)

5.1%
12
Type of Reporting Person (See Instructions)

IA



Item 1.
(a)     Name of Issuer:
Albireo Pharma Inc (the ?Issuer?).
(b)     Address of Issuer?s Principal Executive Offices:
53 State Street, 19th Floor
Boston, MA 02109
Item 2.
(a)     Name of Person Filing:
Chicago Capital LLC
(b)     Address of Principal Business Office or, if None, Residence:
135 South LaSalle Street, Suite 4200
Chicago, IL 60603
(c)     Citizenship:
Illinois
(d)     Title and Class of Securities:
common stock, par value $0.001 per share (?Common Stock?)
(e)     CUSIP No.:
01345P106
Item 3.         If this statement is filed pursuant to ?? 240.13d-1(b) or
240.13d-2(b) or (c), check whether the
person filing is a:
(a)     [_]     Broker or dealer registered under Section 15 of the Act;
(b)     [_]     Bank as defined in Section 3(a)(6) of the Act;
(c)     [_]     Insurance company as defined in Section 3(a)(19) of the Act;
(d)     [_]     Investment company registered under Section 8 of the
Investment Company Act of 1940;
(e)     [X]     An investment adviser in accordance with Rule 13d-1(b)(1)(ii)
(E);
(f)     [_]     An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g)     [_]     A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h)     [_]     A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act
(12 U.S.C. 1813);
(i)     [_]     A church plan that is excluded from the definition
of an investment company under
section 3(c)(14) of the Investment Company Act of 1940;
(j)     [_]     A non-U.S. institution in accordance with Rule 240.
13d-1(b)(1)(ii)(J);
(k)     [_]     Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
If filing as a non-U.S. institution
in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of
institution:
____
Item 4. Ownership
(a)     Amount Beneficially Owned:
        971,885
 (b)    Percent of Class:
        5.1%
 (c)    Number of shares as to which such person has:
        (i)     Sole power to vote or to direct the vote:
                971,885
        (ii)    Shared power to vote or to direct the vote:
                -0-
(iii)   Sole power to dispose or to direct the disposition of:
971,885
(iv)    Shared power to dispose or to direct the disposition of:
-0-
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased
to be the beneficial owner of more than five percent of the class of securities
, check the following [ ].
Item 6. Ownership of more than Five Percent on Behalf of Another Person.
        Not applicable
Item 7. Identification and classification of the subsidiary which acquired the
security being reported on
by the parent holding company or control person.
        Not applicable
Item 8. Identification and classification of members of the group.
        Not applicable
Item 9. Notice of Dissolution of Group.
        Not applicable
Item 10.        Certifications.


SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this
statement is true, complete and correct.
By: Chicago Capital LLC,
its Chief Compliance Officer
Dated:  03/04/2022
/s/Stacey Sargent
Name: Stacey Sargent
Title: Chief Compliance Office
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative.  If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement, provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference.  The name and any title of each person who signs the statement
shall be typed or printed beneath his signature.
Attention:  Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18
U.S.C. 1001).
Page 1 of 1
1297544.3

Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Albireo Pharma Charts.